KBC Group
ACOR

KBC Group’s Acorda Therapeutics ACOR Stock Holding History

KBC Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-405
Closed -$99K – 1485
2019
Q4 		$99K Hold
405
– – ﹤0.01% 1359
2019
Q3 		$140K Buy
405
+372
+1,127% +$202K ﹤0.01% 1303
2019
Q2 		$31K Buy
+33
New +$40.6K ﹤0.01% 1389
2018
Q1 		– Sell
-533
Closed -$1.37M – 1326
2017
Q4 		$1.37M Hold
533
– – 0.01% 700
2017
Q3 		$1.51M Buy
533
+352
+194% +$927K 0.01% 684
2017
Q2 		$428K Sell
181
-103
-36% -$204K ﹤0.01% 981
2017
Q1 		$716K Buy
+284
New +$817K 0.01% 964

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

KBC Group's ACOR Position: Q1 2020 in Review

KBC Group sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 405 shares — an estimated $99K sold.

KBC Group first reported a position in ACOR in Q1 2017 and held it in 7 quarters. The position peaked at $1.51M in Q3 2017. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

  • KBC Group reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
  • KBC Group sold 405 Acorda Therapeutics shares in Q1 2020, an estimated $99K.
  • KBC Group first reported a position in Acorda Therapeutics in Q1 2017 and held it in 7 quarters.
  • KBC Group's Acorda Therapeutics position peaked at $1.51M in Q3 2017.
  • 106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on KBC Group's 13F filing for Q1 2020, filed 4 May 2020.